Lineage Cell Therapeutics (LCTX) Total Current Liabilities (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Total Current Liabilities of $8.1 million for Q1 2026, down 37.75% year-over-year from $13.1 million in Q1 2025, and down 28.32% quarter-over-quarter from $11.4 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $8.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 37.75% year-over-year to $8.1 million; the TTM figure through Mar 2026 stood at $8.1 million (down 37.75% YoY), while the FY2025 annual figure was $11.4 million, down 18.67% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $8.1 million, down from $11.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $25.1 million in Q2 2022, with the low at $8.1 million in Q1 2026.
- The 5-year median for Total Current Liabilities is $15.9 million (2023), against an average of $16.0 million.
- Peak annual rise in Total Current Liabilities reached 271.44% in 2022, while the deepest fall reached 59.71% in 2022.
- Lineage Cell Therapeutics' Total Current Liabilities stood at $19.0 million in 2022, then retreated by 5.38% to $18.0 million in 2023, then dropped by 22.18% to $14.0 million in 2024, then fell by 18.67% to $11.4 million in 2025, then dropped by 28.32% to $8.1 million in 2026.
- Business Quant data shows LCTX's Total Current Liabilities at $8.1 million in Q1 2026, $11.4 million in Q4 2025, and $9.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 8.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.02 Mn |
| Mar 31, 2026 | 8.15 Mn |
| Dec 31, 2025 | 11.37 Mn |
| Sep 30, 2025 | 9.38 Mn |
| Jun 30, 2025 | 10.76 Mn |
| Mar 31, 2025 | 13.09 Mn |
| Dec 31, 2024 | 13.98 Mn |
| Sep 30, 2024 | 13.86 Mn |
| Jun 30, 2024 | 15.28 Mn |
| Mar 31, 2024 | 16.89 Mn |
| Dec 31, 2023 | 17.96 Mn |
| Sep 30, 2023 | 15.88 Mn |
| Jun 30, 2023 | 16.05 Mn |
| Mar 31, 2023 | 17.23 Mn |
| Dec 31, 2022 | 18.98 Mn |
| Sep 30, 2022 | 22.74 Mn |
| Jun 30, 2022 | 25.09 Mn |
| Mar 31, 2022 | 24.59 Mn |
| Dec 31, 2021 | 47.12 Mn |
| Sep 30, 2021 | 8.79 Mn |